CLOs on the Move

Cricket Health

www.crickethealth.com

 
Cricket Health is a specialty kidney care provider of integrated nephrology and dialysis care for people with Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD). Cricket Health delivers world-class, technology-enabled multidisciplinary care both in-person and virtually to achieve the best outcomes possible for patients and the best value for partners, keeping patients healthy and out of the hospital, accelerating access to transplant, and increasing home dialysis adoption. We are committed to aligning the success of our company with those of our partners and the patients whom we serve.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Health Partners

Health Partners, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Health Partners, Inc. is based in Philadelphia, PA. You can find more information on Health Partners, Inc. at www.healthpart.com

Mission Search USA

Mission Search USA is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Qspex Technologies

QSpex embodies the ideal to provide its capital partners best-in-class financial returns, and its customers distinguishable and meaningful value. We will deliver on these fundamentals, while delivering on a higher purpose, advancing the eco-system at-large. We will do this through an inspired vision, integrated ideals, an accountable organization and compassionate leadership.

Quantum Dental Resources

Quantum Dental Resources is a Carmel, IN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.